A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）

Sponsor
Yanqiao Zhang
Study ID
NCT04420130
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab was administered 200mg iv every 3 weeks
  • Chemotherapy — DRUG
    The chemotherapy regimen may be a standard regimen for routine treatment of advanced pancreatic cancer.
  • Ablation — PROCEDURE
    First give pancreatic cancer patients with liver metastases to ablation of liver metastases

Study Details

This is a a single-arm, prospective study of Camrelizumab combined with ablation and chemotherapy for patients with Pancreatic cancer liver metastasis. The main purpose of this study is to evaluate the safety and tolerability of Camrelizumab combined with ablation and chemotherapy as a treatment of Pancreatic cancer liver metastasis.

Key Dates

Start date
Aug 1, 2020
Status verified
Oct 2022
Primary completion
Aug 1, 2022
Completion
Aug 1, 2023

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab combined with ablation and chemotherapy
    First, patients with liver metastases from pancreatic cancer are given ablation of liver metastases, and conventional chemotherapy plus camrelizumab is performed 1 week after surgery. If patients have multiple metastases, ablation treatment needs to be performed in stages, each ablation After 1 week of treatment, sequential chemotherapy + camrelizumab were reinfused, and the efficacy was evaluated every 2 cycles until the disease progressed or the patient could not tolerate it.

Primary Outcome Measure

6-month PFS rate [ Time Frame: From date of starting treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months. ]

Related Studies